A U.S. cannabis company has expressed interest in acquiring Aurora Cannabis Inc., a company based in Edmonton. Aurora has formed a special committee to review the unsolicited bid from Curaleaf Holdings Inc., which aims to purchase all of Aurora’s shares. If successful, the acquisition would create a combined cannabis entity with operations in 17 countries globally. Curaleaf, a company headquartered in Stamford, Connecticut and listed on the Toronto Stock Exchange, decided to make its proposal public after private negotiations with Aurora’s leadership failed.
The proposed deal involves Curaleaf paying Aurora shareholders $4 US per share, along with an additional $0.75 US in cash for each Aurora share. Aurora confirmed receiving letters from Curaleaf outlining the acquisition proposals, with only the July 7 letter detailing the financial terms. Aurora refuted Curaleaf’s claim that it declined to engage with the offer, stating that its lead independent director had been in recent communication with Curaleaf’s CEO.
Aurora will establish a special committee comprising independent directors to assess the offer’s viability and its impact on stakeholders. While expressing interest in Curaleaf’s bid, analysts caution that the current offer undervalues Aurora’s long-term potential. They believe Aurora’s market leadership, product portfolio, financial strength, and regulatory expertise position the company for greater value creation in the future.
Curaleaf believes that merging with Aurora would leverage its global distribution network with Aurora’s strong international medical cannabis presence and production capabilities. The combined revenue of both companies over the past year exceeded $1.5 billion US, with Curaleaf anticipating annual cost synergies of at least $40 million US from the acquisition. Curaleaf views the potential merger as beneficial for both sets of shareholders, offering increased exposure to favorable U.S. regulatory trends.